TLSA - Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar | Benzinga
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer and Chief Medical Officer will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December 6th at 3:00 PM ET. The presentation will be focused on Tiziana's recent clinical updates and our Phase 2 trial of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS) and other neuroinflammatory and neurodegenerative diseases such as Alzheimer's disease.
Conference Details:
Conference: Webull LIVE! with Corporate Connect: Biotech Investment Webinar
Date/Time: Wednesday, December 6th at 3:00 PM ET
Presenter: Matthew Davis, Chief Operating Officer & Chief Medical Officer